SCHEMBL29506498

SCHEMBL29506498

CN1CCN(c2ccc(Nc3ncc4c(n3)N3CCN=C3N(c3cccc(F)c3Cl)C4=O)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 11/20 0.54
▸ TNK2 Q07912 1/20 0.48
▸ SRC P12931 2/20 0.46
▸ JAK2 O60674 1/20 0.46
▸ FGFR1 P11362 1/20 0.46
▸ FGFR2 P21802 1/20 0.46
▸ FGFR4 P22455 1/20 0.46
▸ FGFR3 P22607 1/20 0.46
▸ PLK1 P53350 1/20 0.46
▸ ALK Q9UM73 1/20 0.45
▸ CDK4 P11802 1/20 0.45
▸ CCND1 P24385 1/20 0.45
▸ CTSC P53634 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ NTRK1 P04629 1/20 0.44
▸ SIK2 Q9H0K1 1/20 0.44
▸ DCLK1 O15075 1/20 0.44
▸ LRRK2 Q5S007 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21373384 1.00 WEE1 (0.54) WEE1TNK2SRCJAK2FGFR1
SCHEMBL29506492 0.92 WEE1 (0.55) WEE1TNK2SRCJAK2FGFR1
SCHEMBL21373290 0.92 WEE1 (0.55) WEE1TNK2SRCJAK2FGFR1
SCHEMBL21373346 0.89 WEE1 (0.65) WEE1SRCFGFR1FGFR2FGFR4
SCHEMBL29506474 0.89 WEE1 (0.65) WEE1SRCFGFR1FGFR2FGFR4
SCHEMBL20180608 0.89 WEE1 (0.55) WEE1TNK2SRCJAK2FGFR1
SCHEMBL29506508 0.89 WEE1 (0.55) WEE1TNK2SRCJAK2FGFR1
SCHEMBL21373363 0.86 WEE1 (0.61) WEE1SRCFGFR1FGFR2FGFR4
SCHEMBL29506442 0.86 WEE1 (0.61) WEE1SRCFGFR1FGFR2FGFR4
SCHEMBL29506538 0.86 WEE1 (0.62) WEE1SRCFGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN claimed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN claimed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO claimed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO claimed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN claimed
WO-2025074275-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS REPARE THERAPEUTICS, INC. (CA) 2025-04-10 — — WO disclosed
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN disclosed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN disclosed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO disclosed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN disclosed
Send feedback